Smart Leasing Strategies for Growth-Phase Companies

The scientific landscape is undergoing a lot of change and challenges. As it evolves, biotechnology and research companies need to remain nimble, and open to financial opportunities and solutions.

Highlights

• How leading cancer diagnostics and analytical testing labs expanded capabilities using flexible equipment leasing.
• Ways to reduce CAPEX strain and access the latest instrumentation with 0% interest promotions.
• Why leasing is becoming a core growth strategy for scaling research organizations.

Article Table of Contents

• Case Study 1: Expanding Cancer Diagnostics Capacity
• Case Study 2: Refreshing an Analytical Lab Fleet in a Growth Phase
• Key Takeaways

Growth-phase companies in diagnostics, analytical testing, and metabolomics all share a common challenge: how to expand capacity, refresh critical equipment, and manage cash flow effectively.

Leasing solutions are proving to be a powerful financial strategy to ensure the equipment that’s needed is readily available. Scientific equipment leasing can enable teams to standardize and update their technology without slowing momentum.

Below, we highlight two success stories that showcase how leading organizations scaled successfully with equipment leasing and financial solutions.

Case Study 1: How Equipment Leasing Helped Expand Cancer Diagnostics Capacity

A leading clinical diagnostics company focused on cancer screening faced competing capex priorities across multiple research sites. One site needed greater sample throughput for a lung cancer screening test, while another wanted to bring proteomics capabilities in-house.

Budget limitations forced leadership to consider proceeding with only one project.

The Leasing Solution
By approving a multi-year lease for each site and leveraging a 0% interest promotion, both labs acquired the essential equipment they needed. This no interest financing solution allowed the company to spread out the cost of acquiring multiple instruments, expand capabilities at both sites, and advance cancer diagnostics simultaneously.

---

Case Study 2: How Equipment Leasing Helped Refresh an Analytical Lab Fleet in a Growth Phase

A high growth phase analytical testing lab needed to upgrade out-of-date instruments. The lab’s leadership was concerned about the heavy capital expenditure, as well as the potential downtime that could slow productivity during such a critical expansion period.

The Leasing Solution:
The lab was approved for a multi-year lease covering multiple Ultra-High-Performance Liquid Chromatography (UHPLCs) and Gas Chromatography. This long-term leasing structure reduced upfront capital strain, lowered overall CAPEX, and enabled the lab to upgrade its fleet without disrupting ongoing operations. The result: improved productivity and better readiness for future growth.

Key Takeaways

• Flexibility fuels growth: Leasing helped enable each organization to move forward without waiting for larger budget approvals.
• Lower CAPEX, higher impact: Long-term leases and promotional interest rates helped conserve cash for strategic initiatives.
• Future-proofing technology: Companies gained the latest instruments needed for scientific advancement while avoiding the burden of large, one-time purchases.

For growth-phase companies, equipment leasing isn’t just a financing tool—it’s a strategic enabler that helps teams scale faster, stay technologically current, and manage cash flow with confidence.

---

Let’s Move Science Forward—Together

Learn more about flexible financing solutions available that help you stay current, competitive, and move forward with confidence.

Thermo Fisher Financial Solutions is committed to ensuring that science continues, even in uncertain times. We’re not just providing financing—we’re providing momentum.

• Explore Thermo Fisher Financial Solutions
• Learn more about 0% interest promotion.
• Connect with a specialist.

Explore additional case studies.

All offerings and solutions are subject to credit approval. Determination of eligibility is at the sole discretion of the Thermo Fisher Financial Solutions credit committee. Financing is subject to standard contract terms and conditions. Offerings may vary and are subject to change without notice.